Kalobios Pharmaceuticals, Inc.

Engen Bio, Inc.

Dyadic International, Inc.

Mark Baer

Geoffrey T Yarranton

Christopher Robert Bebbington

Kenneth Luehrsen

Varghese Palath

Mark Alfenito

Doris Bucher

Mark Aaron Emalfarb

Nenad Tomasevic

David Martinez

Jason Williams

Jean Dubayle

Marie-Pierre Kazek

Swathi Sujatha-Bhaskar

Richard Kensinger

Isabelle Legastelois

Mark R Alfenito

Teunis Cornelis Verwoerd

Marie-Clotilde Bernard

Recombinant expression of influenza virus surface proteins in the fungusstrain C1 is provided. The recombinant proteins are for use in influenza vaccine compositions.

Production of flu vaccine in

The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.

Influenza vaccine and therapy

The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.

Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow

The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.

Anti-EMR1 antibodies

The current invention provides high-affinity antibodies to thePcrV protein that have reduced immunogenicity when administered to treatinfections.

[object Object]

Growing community of inventors

San Francisco, CA, United States of America

Mark Baer